小猪视频app

Form: 10QSB

Optional form for quarterly and transition reports of small business issuers

November 14, 1996

Documents

COMPUTATION OF NET (LOSS) PER COMMON SHARE

Published on November 14, 1996


Exhibit 11

CYTOCLONAL PHARMACEUTICS INC.


COMPUTATION OF NET (LOSS) PER COMMON SHARE
(unaudited)






Three Months Nine Months
Ended September 30, Ended September 30,
1995 1996 1995 1996
---------- --------- ----------- -----------

Net (loss) ($678,000) ($808,000) ($2,110,000) ($2,128,000)

Add cumulative preferred dividend (79,000) (79,000) (238,000) (238,000)
--------- --------- ----------- -----------
NET (LOSS) USED FOR COMPUTATION ($757,000) ($887,000) ($2,348,000) ($2,366,000)
========= ========= =========== ===========
Weighted average number of
common shares outstanding 5,249,000 7,687,361 5,229,667 7,631,373
--------- --------- ----------- -----------
Shares issuable upon exercise of stock
options and warrants, net of shares
assumed to be repurchased (1) 0 0 98,277 0
--------- --------- ----------- -----------
Shares used for computation 5,249,000 7,687,361 5,327,944 7,631,373
========= ========= =========== ===========
Net (loss) per common share ($0.14) ($0.12) ($0.44) ($0.31)
========= ========= =========== ===========


Notes and Assumptions:

(1) The Company issued common stock and common stock equivalents for
consideration below the initial public offering price of $5.00.
Consequently, in accordance with Staff Accounting Bulletin 83 (during the
periods covered by statements of operation included in the registration
statement) the following methodology was used in determining weighted
average shares outstanding:
Stock issued in a one year period immediately prior to the offering
was treated as outstanding through June 30, 1995 and repurchase of
shares using the treasury stock method at an offering price of $5.00.